Moubarak Rana S, Koetz-Ploch Lisa, Mullokandov Gavriel, Gaziel Avital, de Pablos-Aragoneses Ana, Argibay Diana, Kleffman Kevin, Sokolova Elena, Berwick Marianne, Thomas Nancy E, Osman Iman, Brown Brian D, Hernando Eva
Department of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Interdisciplinary Melanoma Cooperative Group (IMCG), New York University (NYU) Cancer Institute, New York, NY, United States.
Front Oncol. 2022 Apr 4;12:852952. doi: 10.3389/fonc.2022.852952. eCollection 2022.
Melanoma is a highly prevalent cancer with an increasing incidence worldwide and high metastatic potential. Brain metastasis is a major complication of the disease, as more than 50% of metastatic melanoma patients eventually develop intracranial disease. MicroRNAs (miRNAs) have been found to play an important role in the tumorigenicity of different cancers and have potential as markers of disease outcome. Identification of relevant miRNAs has generally stemmed from miRNA profiling studies of cells or tissues, but these approaches may have missed miRNAs with relevant functions that are expressed in subfractions of cancer cells. We performed an unbiased screen to identify miRNAs with potential functions as metastasis suppressors using a lentiviral library of miRNA decoys. Notably, we found that a significant fraction of melanomas that metastasized to the brain carried a decoy for miR-124a, a miRNA that is highly expressed in the brain/neurons. Additional loss- and gain-of-function validation studies confirmed miR-124a as a suppressor of melanoma metastasis and particularly of brain metastasis. miR-124a overexpression did not inhibit tumor growth , underscoring that miR-124a specifically controls processes required for melanoma metastatic growth, such as seeding and growth post-extravasation. Finally, we provide proof of principle of this miRNA as a promising therapeutic agent by showing its ability to impair metastatic growth of melanoma cells seeded in distal organs. Our efforts shed light on miR-124a as an antimetastatic agent, which could be leveraged therapeutically to impair metastatic growth and improve patient survival.
黑色素瘤是一种高度常见的癌症,在全球范围内发病率不断上升,且具有很高的转移潜能。脑转移是该疾病的主要并发症,因为超过50%的转移性黑色素瘤患者最终会发生颅内病变。已发现微小RNA(miRNA)在不同癌症的肿瘤发生中起重要作用,并具有作为疾病预后标志物的潜力。相关miRNA的鉴定通常源于对细胞或组织的miRNA谱分析研究,但这些方法可能遗漏了在癌细胞亚群中表达的具有相关功能的miRNA。我们使用miRNA诱饵慢病毒文库进行了一项无偏筛选,以鉴定具有潜在转移抑制功能的miRNA。值得注意的是,我们发现转移至脑的黑色素瘤中有很大一部分携带了miR-124a的诱饵,miR-124a是一种在脑/神经元中高表达的miRNA。额外的功能缺失和功能获得验证研究证实miR-124a是黑色素瘤转移尤其是脑转移的抑制因子。miR-124a过表达并不抑制肿瘤生长,这突出表明miR-124a特异性地控制黑色素瘤转移生长所需的过程,如播种和外渗后的生长。最后,我们通过展示其削弱接种于远端器官的黑色素瘤细胞转移生长的能力,为这种miRNA作为一种有前景的治疗剂提供了原理证明。我们的研究揭示了miR-124a作为一种抗转移剂的作用,可在治疗上加以利用以削弱转移生长并提高患者生存率。